anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
According to the embodiments described herein, a methods for inhibiting small ubiquitin-like modifier enzymes in a cell are provided. Such methods may include administering certain substituted pyrrolo[2,3-b]-quinoxalines to the cell. In some aspects, the small ubiquitin-like modifier enzyme is SUMO E1 or SUMO E2. In some aspects, the methods may be used to inhibit a cancer cell in vitro (e.g., grown in culture) or in vivo (e.g., as part of a tumor in a subject). In other embodiments, methods for treating a cancer, degenerative diseases and viral infection are provided. Such methods may include administering an effective amount of a pharmaceutical composition to a subject having cancer. The pharmaceutical composition may include a small ubiquitin-like modifier inhibitor compound. In some embodiments, the method for treating a disease may further comprise administering one or more DNA-damaging therapy in combination with administration of the pharmaceutical composition.
Greater occipital nerve block (GONB) will be applied to medial of the occipital artery which localized at the medial one-third of the superior nuchal line between the occipital tubercle and mastoid process. GONB solution is prepared with 1 ml triamcinolone (40mg), 2 ml bupivacaine (10 mg) and 1 ml 0,9% sodium chloride (NaCl). The injection is performed using a 22 gauge (G) × 1¼" (0.7 × 40mm) injector when the patient is lying prone on the table. The scalp is cleaned with iodine before procedure and injections are performed bilaterally with a volume of 2 mL after negative aspiration for blood. Supratrochlear nerve block (STNB) is applied 1 cm medial to superior orbital fissure using a mixture of 8 mg bupivacaine and 1.4 ml 0,9% NaCl. STNB is performed bilaterally with a volume of 1.5 mL after negative aspiration for blood.
Participants with r/r DLBCL,PMBCL,TFL,or high-grade B-cell lymphoma(HGBCL)after 2 systemic lines of therapy will receive optional bridging therapy(dexamethasone 20mg to 40mg,eitherorally or IV daily for 1 to 4 days or 1g/m\^2 of high-dose methylprednisolone(HDMP)for 3 days with rituximab at 375mg/m\^2 weekly for 3 weeks or bendamustine 90 mg/m\^2 on Days 1 and 2 and rituximab 375mg/m\^2 on Day 1),conditioning chemotherapy(fludarabine 30mg/m\^2 IV and cyclophosphamide 500mg/m\^2 IV)on Days -5,-4, and -3;followed by single infusion of axicabtagene ciloleucel CAR transduced autologous T cells IV at a target dose of 2 x 10\^6 anti-CD19 CAR T cells/kg of BW. Participants will receive a prophylactic regimen of levetiracetam(750 mg orally or IV twice daily(BID)starting on Day 0).Participants will receive tocilizumab(initiated on persistent Grade 1 cytokine release syndrome(CRS)for over 24 hours)and dexamethasone(persistent Grade 1 CRS for over 72 hours and at onset of Grade 1 neurologic toxicity).
The present invention provides methods and products for inhibiting neutrophil adhesion and neutrophil aggregation. The invention includes a method for treating a subject to inhibit neutrophil adhesion and neutrophil aggregation by administering 16-hydroxyeicosatetraenoic acid (16-HETE) to the subject. 16HETE is an arachidonic acid metabolite. The invention also includes a pharmaceutical preparation of 16-HETE. Methods and products are also provided for treating thromboembolic stroke. The method involves the administration of 16-HETE in combination with a thrombolytic agent to a patient suffering from thromboembolic stroke. Preferably, the 16-HETE is 16(R)-HETE and the thrombolytic agent is tPA. The product is a pharmaceutical preparation of 16HETE and a thrombolytic agent and a pharmaceutically acceptable carrier.
Hysterosalpingography (HSG) is a radiographic evaluation during which a radio-opaque medium is inserted through the cervical canal in order to define the size and shape of the uterine cavity and patency of the fallopian tubes. The utility of HSG is an integral part of the evaluation of infertile women for intrauterine pathology. In some cases, HSG can be a painful procedure. Poor pain control can limit the quality of the study due to inability to complete the procedure in cases of extreme discomfort. There is little consensus regarding pain control during HSG, although a number of approaches have been studied. Patients undergoing HSG are typically advised to premedicate with ibuprofen, which is consistent with the current standard of care. This study will assess pain control using a benzocaine spray (in addition to ibuprofen) in patients undergoing routine HSG at the Hospital of the University of Pennsylvania. All patients who present to the Hospital of the University of Pennsylvania for HSG will be eligible for the study. Benzocaine spray versus a placebo spray will be applied to a tenaculum (a surgical hooklike instrument used to grasp and hold the cervix). The tenaculum will then be applied to the cervix prior to HSG and pain relief will be assessed at 3 time intervals: 0, 5, and 30 minutes. The primary outcome is the mean difference in patients pain score and will be measured using the Visual Analogue Scale (VAS) which has been shown to be a valid and reliable scale. The secondary outcome will assess patient satisfaction in each group using a validated patient satisfaction survey. The study design will be prospective, randomized, placebo controlled, and double blinded.
Participants will be provided orange juice for 84 days in this arm. After 28 days wash-out period, participants will receive Fanta for 84 days.
Methyl-CpG-binding domain protein 2 (Mbd2), a reader of DNA methylation, has been implicated in different types of malignancies, including breast cancer. However, the exact role of Mbd2 in various stages of breast cancer growth and progression in vivo has not been determined. To test whether Mbd2 plays a causal role in mammary tumor growth and metastasis, we performed genetic knockout (KO) of Mbd2 in MMTV-PyMT transgenic mice and compared mammary tumor progression kinetics between the wild-type (PyMT-Mbd2+/+) and KO (PyMT-Mbd2-/-) groups. Our results demonstrated that deletion of Mbd2 in PyMT mice impedes primary tumor growth and lung metastasis at the experimental endpoint (postnatal week 20). Transcriptomic and proteomic analyses of primary tumors revealed that Mbd2 deletion abrogates the expression of several key determinants involved in epithelial-to-mesenchymal transition, such as neural cadherin (N-cadherin) and osteopontin. Importantly, loss of the Mbd2 gene impairs the activation of the PI3K/AKT pathway, which is required for PyMT-mediated oncogenic transformation, growth, and survival of breast tumor cells. Taken together, the results of this study provide a rationale for further development of epigenetic therapies targeting Mbd2 to inhibit the progression of breast cancer.
Patients in the placebo group will receive the stable daily dose divided into 2 doses with meals of the optimal biological dose determined in stage I every 12 hours for the duration of standard therapy. The patient will self-administer the phytomedicine until completing the established treatment days. The taking of the phytomedicine will only be suspended 3 days before each cycle of standard therapy and will restart 3 days after having passed the cycle. That is, in the anthracycline and cyclophosphamide (AC) phase, the patient will start taking the phytomedicine 3 days after having received their standard chemotherapy cycle and will suspend it 3 days before the next cycle begins. For the taxane phase, the patient will take the P2Et without suspension during the treatment cycles.
The present invention relates to medicine liquid for treating influenza viruses and a preparation method thereof. Grain wine is added with earthworm juice, garlic, ginger juice, orange peel, honeysuckle flower, aurantii immaturus and cane sugar, wherein the earthworm juice is formed from earthworms with white sugar. The medicine liquid adds various components of the earthworm juice in the grain wine, takes the advantages of the earthworm juice and makes the disadvantages. Thus, the grain wine and the earthworm are mutually promoted. Therefore, the present invention has obvious killing function for influenza viruses. The medicine liquid is checked by a virus disease control institute of the academy of medical sciences in the HuBei province, and is proved that the present invention has obvious killing function for A 3 type influenza viruses when used in the proportion of 1: 10 for a vitro test. When the medicine liquid is used for treating virus cold, the virus cold can be cured in 1 to 2 days. When the present invention is used for treating influenza fever, a patient only need take 30 to 50 ml of the medicine liquid. Thus, the body temperature of the patient can be normal in 30 minutes.
PROBLEM TO BE SOLVED: To provide recombinant Lactobacillus with decreased lipoteichoic acid to reduce inflammatory responses.SOLUTION: According to the present invention, there are provided a method and composition for treating or preventing an inflammatory disorder. The compositions comprises a recombinant bacterium genetically modified to decrease the display of lipoteichoic acid on the cell surface. The method comprises administering to a subject a recombinant bacterium modified to decrease the display of lipoteichoic acid on the cell surface. Administration of the recombinant bacterium promotes a desired therapeutic response. The recombinant bacterium may be administered in a single dose or series of doses. The method is advantageously used in treating or preventing a variety of inflammatory disorders including, for example, treating or preventing inflammatory bowel disease, colitis, or Crohn's disease.SELECTED DRAWING: None
PURPOSE:To provide a plaster having a three-layer structure composed of a drug-storage layer, an assistant layer and a substrate layer and capable of surely and effectively administering a proper kind of drug at a sufficient amount according to the purpose of treatment. CONSTITUTION:The objective plaster is composed of (A) a drug-storage layer composed of a water-containing hydrophilic polymer matrix containing a drug (e.g. anti-inflammatory agent, a local anesthetic, a hypotensor, a hypotensive diuretic, etc.), its dissolving agent and transcutaneous absorbefacient, (B) an assistant layer laminated to said drug-storage layer and composed of a water- containing hydrophilic polymer matrix at least containing a transcutaneous absorbefacient and free from the dissolving agent of the above drug and (C) an air-permeable substrate layer (e.g. porous synthetic resin film, paper, nonwoven fabric, etc.) bonded to the assistant layer. If necessary, various components such as plasticizer, dispersing agent, stabilizer, etc., may be added to the matrix forming the above drug-storage layer and the assistant layer.
Participants will receive cemiplimab 350 mg IV at least 3 weeks prior to surgical resection. After surgery they will continue to receive 350 mg cemiplimab every 3 weeks for up to 8 additional doses.
The invention provides a ganoderma lucidum wall-broken decoction piece and a preparation method thereof, and relates to a ganoderma lucidum wall-broken decoction piece and a preparation method thereof. The particle size distribution D90 of the Ganoderma wall-broken decoction pieces is 35.5-42.5 μm. The content of ganoderan in the ganoderma wall-broken decoction pieces is 0.95-1.1mg/g calculated by anhydrous glucose. The triterpene and sterol contents of the Ganoderma wall-broken decoction pieces are 0.55-0.7mg/g calculated by oleanolic acid. The limit of the non-wall-broken cells of the ganoderma wall-broken decoction pieces is 0-5 while the particle size of the ganoderma wall-broken decoction pieces is ensured to be smaller, so that the ganoderma wall-broken decoction pieces are convenient to brew and drink, the human body can absorb the active ingredients of ganoderma, the treatment efficiency of a patient is improved, and precious traditional Chinese medicine resources are saved. During the preparation process of the ganoderma wall-broken decoction pieces, ganoderma lucidum polysaccharide, triterpene and sterol are well kept. The ganoderma lucidum polysaccharide, the triterpene and the sterol are main effective components of ganoderma lucidum, and the ganoderma lucidum wall-broken decoction pieces are ensured to have higher medicinal value.
PURPOSE: A method for overcoming tolerance of a target anticancer agent is provided to block a signal transduction system related to tolerance of an insulin-like growth factor(IGF) target monoclonal antibody and an analogous anticancer agent thereof, and to overcome tolerance with respect to the target anticancer agent. CONSTITUTION: A pharmaceutical composition for suppressing tolerance of a target anticancer agent contains one or more selected from a group consisting of integrin beta3 neutralizing antibody, integrin beta3 siRNA, Src inhibitor, and Src siRNA. A target anticancer agent is IGF-1R(insulin-like growth factor-1 receptor) target anticancer agent. The target anticancer agent is an anti-IGF-1R monoclonal antibody. An anticancer aid contains one or more selected from a group consisting of integrin beta3 neutralizing antibody, integrin beta3 siRNA, Src inhibitor, and Src siRNA and increases an anti-proliferative effect. A method for enhancing an anticancer effect comprises a step of alternately administering one or more selected from a group consisting of integrin beta3 neutralizing anbibody, integrin beta3 siRNA, Src inhibitor, and Src siRNA, or a pharmaceutically acceptable salt thereof with the target anticancer agent to an individual.
The present invention relates to in vivo imaging, and in particular to Magnetic Resonance Imaging (MRI). The present invention provides a pharmaceutical formulation suitable for use in MRI procedures and which provides advantages over known such formulations. Particular dosages of the pharmaceutical formulations of the invention are also contemplated, as well as the use of the dosages in vivo imaging methods. The present invention provides for the simultaneous administration of a liver-specific agent and a second MR contrast agent which is able to better/further enhance the dynamic vascular phase in a patient. The method of the invention has the advantages of simplicity and patient comfort compared to sequential injections. Furthermore, the method of the present invention provides the advantage that a lower cumulative dose of contrast agent can be achieved.
Patients with melanoma, NSCLC, ovarian cancer, or sarcoma will be enrolled. Patients will receive CMB305, a sequential regimen of LV305 and G305. Two cohorts are planned based on LV305 dose.
Exposure-response relationships for Grade 3 or 4 hypercholesterolemia and for any Grade 3 or 4 adverse reaction were observed at steady-state exposures achieved at the recommended dosage, with higher probability of the occurrence of adverse reactions with increasing lorlatinib exposure.

Cardiac Electrophysiology

In 295 patients who received LORBRENA at the recommended dosage of 100 mg once daily and had an ECG measurement in Study B7461001, the maximum mean change from baseline for PR interval was 16.4 ms (2-sided 90% upper confidence interval [CI] 19.4 ms). Among the 284 patients with PR interval <200 ms at baseline, 14% had PR interval prolongation ≥200 ms after starting LORBRENA. The prolongation of PR interval occurred in a concentration-dependent manner. Atrioventricular block occurred in 1% of patients.

In 275 patients who received LORBRENA at the recommended dosage in the activity-estimating portion of Study B7461001, no large mean increases from baseline in the QTcF interval (i.e., >20 ms) were detected.
Test food group of subject need to comsume 50g available carbohydrate of test food. One test food for one ocassion. Reference food need to comsume same 50g available carbohydrate of reference food, usually white bread or glucose syrup.
A steam therapy equipment including a vessel for heating a mixture of water and organic materials, a compressor to inject pressurized air into the vessel producing pressurized steam. The pressurized steam is conducted into the equipment via one or more valves. The therapy equipment is formed from at least one panel and may include a supporting frame. The therapy equipment includes a temperature sensor to measure the temperature inside the therapy equipment when pressurized steam is admitted via the valves. A patient enters the equipment and is exposed to the pressurized steam, causing dilation of the skin pores of the patient, whereby toxins are removed from the patient. One or more applicators may conduct pressurized steam to specific portions of the body of the patient. The patient may be provided with a portion of the mixture to consume as part of the steam therapy treatment.
Nelfilcon A contact lenses worn first, with filcon II 3 contact lenses worn second. Both products worn in both eyes on a daily wear, daily disposable basis for one week each.
The invention relates to a Chinese herbal medicine medicament for curing urinary incontinence belonging to a traditional Chinese medicine medicament field. The technical proposal is that the invention is allocated according to daily dose, and comprises ephedra 6 grams, almond 10 grams, plaster stone 30 grams, raw hay 3 grams, white atractylodes rhizome 10 grams, white peony root 10 grams, ledebouriella root 6 grams, dried orange peel 6 grams, cimicifuga foetida 3 grams, and kudzu root 6 grams. The invention is decocted in water for taking. The invention has the effects that the invention mainly combines aftercare and treatment, which has a good curing effect for curing urinary incontinences which are caused by various reasons. Clinical trials demonstrates that the effective rate of the invention can reach 90 percent. And the invention has the advantages of fast efficacy and little side effect.
PCT No. PCT/SE91/00541 Sec. 371 Date Apr. 8, 1993 Sec. 102(e) Date Apr. 8, 1993 PCT Filed Aug. 16, 1991 PCT Pub. No. WO92/03159 PCT Pub. Date Mar. 5, 1992A peptide comprising the amino acid sequence: U-O-X-glu-Z or O-X-glu-Z-ala-glu, wherein: U is an amino acid residue selected from val and ile; O is an amino acid residue selected from ala and thr: X is an amino acid residue selected from asp and glu: and Z is an amino acid residue selected from ile and val: the use of the peptide in the preparation of a vaccine; a composition for vaccination against malaria induced by Plasmodium falciparum, comprising such peptide in admixture with a pharmaceutically acceptable carrier; and a method of inducing immunity against malaria induced by Plasmodium falciparum, which comprises administering to a person in need of such immunity an effective amount of said composition.
PROBLEM TO BE SOLVED: To obtain a composite powder having ultraviolet-intercepting effect, suppressed activity, excellent stability and safety and excellent touch in use, by compositing a heat-treated suppressed-activity zinc oxide powder with an organic powder and to obtain a cosmetic. SOLUTION: A zinc oxide powder having a mean primary particle diameter of 5nm-10μm, especially microparticulate zinc oxide having a mean primary particle diameter of 5-100nm itself has strong activity and therefore its activity is most greatly influenced by treatment of lowering activity. A suppressed- activity zinc oxide powder obtained by heat-treating the zinc oxide powder by directly heating it in a vessel such as a crucible at 600-1,700 deg.C for 0.1-48hr or by irradiating it with electromagnetic waves is used. It is also possible that the obtained powder is subjected to surface treatment such as silicone treatment, silicone resin treatment or silane treatment. The organic powders used include resin powders, organic colorants, dyes, etc., varying in size and shape.  The compositing ratio is desirably such that the ratio of the suppressed-activity zinc oxide powder to the organic powder is 1:99 to 99:1 by weight.
Using intensity-modulated radiation therapy (IMRT) or volumetric arc therapy (VMAT), the choice of which is determined by the radiation oncologist, patients will be treated in \< 5 fractions every other day. The total treatment dose will be between 45 and 54 Gy in \< 5 fractions per standard of care. All patients will be followed for one year. Patients will be assessed for toxicity by their radiation oncologist at 4 to 6 weeks post-RT and during chemotherapy at the discretion of their medical oncologist. Follow up after completion of all treatment will consist of CT chest scans at 6 and 12 months post-SBRT and toxicity assessments every 3 months from the end of SBRT for one year. FDG PET/CT scans and Pulmonary Function Tests (PFTs) will be obtained at 3 months and 9 months after SBRT.
According to the score obtained with the onco geriatric evaluation, patients with a score between 159 and 120 will receive an hypo fractionated radiotherapy (42,56 Grays in 16 fractions). This scheme of radiotherapy is already used in the usual practice, but not allocated according to a score obtained at an oncogeriatric evaluation.
It is unclear whether metabolic health corresponds to reduced oncogenesis or vice versa. We study Tudor-interacting repair regulator (TIRR), an inhibitor of p53 binding protein 1 (53BP1)-mediated p53 activation, and the physiological consequences of enhancing tumor suppressor activity. Deleting TIRR selectively activates p53, significantly protecting against cancer but leading to a systemic metabolic imbalance in mice. TIRR-deficient mice are overweight and insulin resistant, even under normal chow diet. Similarly, reduced TIRR expression in human adipose tissue correlates with higher BMI and insulin resistance. Despite the metabolic challenges, TIRR loss improves p53 heterozygous (p53HET) mouse survival and correlates with enhanced progression-free survival in patients with various p53HET carcinomas. Finally, TIRR's oncoprotective and metabolic effects are dependent on p53 and lost upon p53 deletion in TIRR-deficient mice, with glucose homeostasis and orexigenesis being primarily regulated by TIRR expression in the adipose tissue and the CNS, respectively, as evidenced by tissue-specific models. In summary, TIRR deletion provides a paradigm of metabolic deregulation accompanied by reduced oncogenesis.
Systems, devices, and methods discussed herein provide improved autonomous agent applications that are configured to generate a diagnosis for input symptoms from labels (e.g., diseases, illnesses, and/or conditions) associated with previously-known cases. Extended discourse trees may be generated that identify multiple discourse trees corresponding to various fragment granularities (e.g., document, paragraph, sentence, phrase, word, etc.) of previously-known cases as well as rhetorical relations between those discourse trees. New symptoms can be provided (e.g., via the autonomous agent) as input. The input can be parsed to identify various fragments of the input and rhetorical relations between the fragments. These fragments can be matched to fragments of previously-known cases by matching nodes of the extended discourse tree. If the rhetorical relations between the input fragments match the rhetorical relations indicated in the extended discourse tree of a previously-known cases, the input may be classified with the same label as those previously-known cases.